Company / Cash & Equivalents
BioLife Solutions, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$33.0M
FY2025
5-year range
$19.4M / $91.5M
FY2021-FY2025
Trend
-63.9%
vs FY2024
Sector context
#144 of 152
Health Care
What the data says
Among 152 Health Care companies, BioLife Solutions, Inc. is in the bottom 5% for cash & equivalents. Cash & Equivalents has fluctuated over the past 10 years, ranging from $1M in FY2016 to $92M in FY2024.
Based on SEC 10-K filings.
$33M in FY2025 with a 5-year CAGR of -18.2%.
Improved from $28M to $33M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +19.3%
- 5-Year CAGR
- -18.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 152This company $33.0M Sector average $1.2B
▼
-97.2% below sector average
Key checks
Key Insights
- 5-year CAGR of -18.2%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 63.9% year-over-year.
- Ranks #144 out of 152 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 4.67 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $33.0M | -63.9% |
| FY2024 | $91.5M | +228.1% |
| FY2023 | $27.9M | +43.5% |
| FY2022 | $19.4M | -72.2% |
| FY2021 | $69.9M | -22.7% |
| FY2020 | $90.4M | +1302.0% |
| FY2019 | $6.4M | -8.3% |
| FY2018 | $7.0M | +5.6% |
| FY2017 | $6.7M | +373.9% |
| FY2016 | $1.4M | -35.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026